Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective-Reference-Cited by-同舟云学术

Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective

Published:2022-08-05 Issue:9 Volume:42 Page:733-746
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Carta Andrea,Del Zompo Maria,Meloni Anna,Mola Francesco,Paribello Pasquale,Pinna Federica,Pinna Marco,Pisanu Claudia,Manchia Mirko,Squassina Alessio,Carpiniello Bernardo,Conversano Claudio^ORCID

Funder

Regione Autonoma della Sardegna

Università degli Studi di Cagliari

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-022-01182-2.pdf

Reference40 articles.

1. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–312.

2. Ferrari A, Somerville A, Baxter A, Norman R, Patten S, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43(3):471–81.